COVID-19 Research Highlights Bidirectional Association Between Liver Physiology and Gut Microbiota

Strategic Insights -

Researchers from the National Institute for Biotechnology and Genetic Engineering College in Pakistan have made significant discoveries regarding the relationship between COVID-19, liver damage, and the gut microbiome. The study, published in the World Journal of Gastroenterology, reveals that the activation of innate immune cells during viral infection and high doses of COVID-19 treatment can lead to liver injury. The study also suggests that gut microbiota influences liver chemistry through its metabolites and that gut dysbiosis during COVID-19 treatment can promote liver inflammation.

Key Takeaways:

  • The COVID-19 virus has been associated with liver abnormalities, including inflammation and damage.
  • The release of cytokines by the activation of innate immune cells and high doses of COVID-19 treatment are major drivers of liver injury.
  • Gut microbiota plays a crucial role in liver chemistry, and gut dysbiosis during COVID-19 treatment can promote liver inflammation.
  • The bidirectional association between liver physiology and gut microbiota (gut-liver axis) can be manipulated to alleviate drug-induced hepatic damage in COVID-19 patients.
  • Research has identified several liver chemistry abnormality markers that can estimate the degree of hepatic inflammation in patients.
  • The study highlights the importance of therapeutic modulation of the gut microbiome to alleviate drug-induced liver damage in COVID-19 patients.

Statistics:

  • 2020: The COVID-19 pandemic began to spread globally.
  • 2023: The World Journal of Gastroenterology published a study on the bidirectional association between liver physiology and gut microbiota in COVID-19 patients.
  • 29(11): The volume and issue number of the World Journal of Gastroenterology where the study was published.
  • 1708-1720: The page numbers of the World Journal of Gastroenterology where the study was published.
  • 10: The number of cases of liver inflammation reported in the study.
  • 7041: The Koll Center Parkway address of Baishideng Publishing Group Inc.
  • 160: The suite number of Baishideng Publishing Group Inc.

Sources:

  • "Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients." World Journal of Gastroenterology, 2023;29(11):1708-1720.
  • Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, Ca, United States (www.wjgnet.com/; www.wjgnet.com/1007-9327/current.htm)
  • Munir Ahmad Anwar, Industrial Biotechnology Division, National Institute for Biotechnology and Genetic Engineering College, Pakistan Institute of Engineering and Applied Sciences (NIBGE-C, PIEAS), Faisalabad 38000, Pakistan.